Sequence: ACTGSTQHQCG
| Experiment Id | EXP002255 |
|---|---|
| Paper | Transdermal siRNA delivery by pH-switchable micelles with targeting effect suppress skin melanoma pr |
| Peptide | SCP |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | siRNA 1 mg/mL (topical application; 60 μL) |
| Mixing Ratio | SHP/siRNA N/P = 10:1; siRNA concentration 1 mg/mL for topical dosing |
| Formulation Format | pH-switchable cationic micelles (SHP) assembled from SCP-HA-PAE |
| Formulation Components | SCP (ACTGSTQHQCG) + hyaluronic acid (HA, MW 8000) + poly(β-amino ester) (PAE) |
| Size Nm | 170.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | C57BL/6 nude mice with subcutaneous B16F10 melanoma xenograft; topical treatment at tumor site |
| Administration Route | topical (transdermal) daily; 60 μL of SHP/siRNA-survivin |
| Output Type | tumor growth inhibition + in vivo gene silencing (IHC) / apoptosis (TUNEL) |
| Output Value | tumor volume <200 mm^3 after 10 weeks; ~10-fold smaller vs controls; survivin down ~75% |
| Output Units | |
| Output Notes | Compared vs PBS, naked siRNA-survivin, and blank SHP; SHP/siRNA-survivin showed necrotic/apoptotic regions and strongest TUNEL signal. |
| Toxicity Notes | No obvious organ damage on H&E (heart, liver, spleen, lung, kidney); no noted physiological complications. |
| Curation Notes |